This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mizejewski, G. J. Articles by MacColl, R. Search for Related Content PubMed PubMed Citation Articles by Mizejewski, G. J. Articles by MacColl, R. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

Review

-Fetoprotein growth inhibitory peptides: Potential leads for cancer therapeutics

Wadsworth Center, New York State Department of Health, Albany, NY

Requests for Reprints: Gerald J. Mizejewski, Wadsworth Center, New York State Department of Health, P. O. Box 509, Albany, NY 12201. Phone: (518) 486-5900; Fax: (518) 457-7893. E-mail: Mizejew{at}wadsworth.org

-Fetoprotein (AFP), known largely as a growth-promoting agent, also possesses a growth inhibitory motif recently identified as an occult epitopic segment of the molecule. This segment, a 34-amino acid stretch termed the growth inhibitory peptide (GIP), has been chemically synthesized, purified, and characterized. The purified 34-mer exhibits complex aggregation behaviors; initially, trimeric oligomers were formed that possess growth inhibitory activity in rodent uterine bioassays. These rodent growth assays have served as a prelude to the anticancer studies that followed. In solution, the trimers convert slowly to dimers containing intrapeptide disulfide bonds; such dimers are inactive in the antigrowth assays. Cysteine-to-alanine analogues of the GIP retain the antigrowth properties, while similar cysteine-to-glycine and cysteine-to-serine analogues demonstrate little, if any, growth regulatory activity. Chemical modifications of the cysteine residues also have little influence on the antigrowth activity of the GIP. Fragments of the 34-mer possess variable growth activities of their own, with an octamer from near the carboxyl terminus displaying estrogen-dependent antigrowth activity similar to that of the 34-mer. It was further observed that the GIP can bind both Zn²⁺ and Co²⁺; the Co²⁺ peptide complex was shown to have a distorted tetrahedral symmetry, involving coordination of two cysteine and two histidine residues. The Zn²⁺-GIP complex had antigrowth activity and did not form the intrapeptide disulfide bond characteristic of the free GIP in aqueous solution. The GIP was tested in vitro for anticancer activity and was found to suppress the growth in 38 of 60 human cancer cell lines, representing nine different cancer types. In vivo studies of the GIP, certain analogues, and its fragments revealed anticancer activities in both isograft and xenograft animal tumor transplants. Furthermore, the 2C 2A replacement analogue was active against a breast tumor in vivo and in vitro and a prostate cancer in vitro. Thus, it is proposed that the GIP, its analogues, and its fragment peptides can potentially serve as lead compounds for cancer therapeutics.

Received 6/11/03; revised 7/31/03; accepted 9/ 2/03.

This article has been cited by other articles:

				J. Shen, J. Liu, Y. Xie, B. A. Diwan, and M. P. Waalkes Fetal Onset of Aberrant Gene Expression Relevant to Pulmonary Carcinogenesis in Lung Adenocarcinoma Development Induced by In Utero Arsenic Exposure Toxicol. Sci., February 1, 2007; 95(2): 313 - 320. [Abstract] [Full Text] [PDF]